Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05473338
Other study ID # CRPS-MB 2021-6735
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date April 14, 2022
Est. completion date June 30, 2024

Study information

Verified date October 2022
Source McGill University Health Centre/Research Institute of the McGill University Health Centre
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to investigate, for the first time, whether gut bacteria composition and function of patients with CRPS differ from those of healthy adults. Samples of stool, urine and blood will be collected from patients with CRPS and from healthy adults. The type and function of bacteria of CRPS patients will be analyzed and compared to those of healthy adults to test if potential differences could explain the mechanism/s involved with the development of CRPS.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 250
Est. completion date June 30, 2024
Est. primary completion date October 14, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: 1. Women and men over the age of 18, diagnosed with CRPS of the upper or lower limb according to the Clinical Budapest Criteria, with a duration of 6 months and over (for the 1st study group). 2. Healthy women and men over the age of 18, who share a household with a CRPS patients participating in the study (for the 1st control group). 3. Healthy women and men over the age of 18 (for the 2nd control group). 4. Be able to read and write in either French, English or Hebrew. Exclusion criteria: 1. Any major illness (eg. malignancy, active inflammatory disease, metabolic disease, etc.) 2. Pregnancy 3. Chronic pain conditions (other than CRPS in the patients group) 4. Acute illness of any type in the preceding 1 month 5. Use of systemic antibiotics in the preceding 1 month 6. Change in any other regularly taken medications in the past 1 month 7. Substantial dietary / gastrointestinal alterations in the past 1 month. The inclusion/exclusion criteria were set to reduce the risk of confounding factors that could affect gut microbiota composition.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Stool and blood samples
fecal microbiome and metabolomics, as well as metabolites in plasma
Other:
Physical examination
physical examination performed by a physician to confirm CRPS diagnosis and assess patient's eligibility to participate in the study. The exam will include skin temperature measured using a laser/infrared skin thermometry.
Questionnaires
Questionnaires measuring pain level, sleep, mood and diet parameters.

Locations

Country Name City State
Canada Alan Edwards Pain Management Unit - Montreal General Hospital Montreal Quebec

Sponsors (3)

Lead Sponsor Collaborator
McGill University Health Centre/Research Institute of the McGill University Health Centre Louise and Alan Edwards Foundation, Rambam Health Care Campus

Country where clinical trial is conducted

Canada, 

References & Publications (4)

Birklein F, Ajit SK, Goebel A, Perez RSGM, Sommer C. Complex regional pain syndrome - phenotypic characteristics and potential biomarkers. Nat Rev Neurol. 2018 May;14(5):272-284. doi: 10.1038/nrneurol.2018.20. Epub 2018 Mar 16. Review. — View Citation

Birklein F, O'Neill D, Schlereth T. Complex regional pain syndrome: An optimistic perspective. Neurology. 2015 Jan 6;84(1):89-96. doi: 10.1212/WNL.0000000000001095. Epub 2014 Dec 3. Review. — View Citation

Harden RN, Bruehl S, Stanton-Hicks M, Wilson PR. Proposed new diagnostic criteria for complex regional pain syndrome. Pain Med. 2007 May-Jun;8(4):326-31. — View Citation

Minerbi A, Gonzalez E, Brereton NJB, Anjarkouchian A, Dewar K, Fitzcharles MA, Chevalier S, Shir Y. Altered microbiome composition in individuals with fibromyalgia. Pain. 2019 Nov;160(11):2589-2602. doi: 10.1097/j.pain.0000000000001640. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Gut microbiome composition Assessment of genomic composition of the gut bacteria by differential abundance analysis will be performed using 16S rRNA (Genome-Quebec) 1 day
Primary Presence of stool microbiota-related metabolites affecting host physiology Concentration of bile acids and short-chain-fatty-acids through Metabolomics analysis (Metabolon, USA). 1 day
Secondary Short-form health-questionnaire (SF12) score A 12-item measure of health-related quality of life, validated in a variety of population groups 1 day
Secondary Brief Pain Inventory (BPI) score A 12-item questionnaire evaluating function level and disability among pain patients 1 day
Secondary Patient Health Questionnaire (PHQ-9) score A 9 item inventory rated on a 4 point Likert-type scale used for screening for depression and anxiety 1 day
Secondary Pittsburg Sleep Quality Index (PSQI) scores A standardized self-administered questionnaire for the assessment of subjective sleep quality 1 day
See also
  Status Clinical Trial Phase
Recruiting NCT00377468 - Effect of Delta-9-Tetrahydrocannabinol on the Prevention of Chronic Pain in Patients With Acute CRPS (ETIC-Study) Phase 2
Completed NCT01618578 - The Rubber Hand Illusion (RHI) in Patients With CRPS N/A
Completed NCT02467556 - Psychological Intervention and Physiotherapy With Medication Improves CRPS Patients Outcome Phase 4
Withdrawn NCT02031211 - TNF-alpha Inhibition in CRPS: A Randomized Controlled Trial N/A
Recruiting NCT01601925 - Distances From Cricoid Cartilage to the Targets of Stellate Ganglion Block N/A
Withdrawn NCT04709757 - Comparison of Continuous and Burst High Frequency Spinal Cord Stimulation Paradigms N/A
Completed NCT00558753 - Prospective, Randomized Controlled Trial on Perioperative Pregabalin to Reduce Late-onset CRPS After TKA Phase 2